A study to back accelerated approval is to start next year, but the prospect of seeing a fully greenlit Padcev before then looms large.

Asco data suggest that the TROP2 ADC Merck & Co licensed from Kelun is at least as good as Gilead and Astra/Daiichi’s assets.